Drug Profile


Alternative Names: Anti-CD19-CAR retroviral vector-transduced autologous T cells - University of Pennsylvania; Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania; CART-019; CART-19; CART-19 cells; Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis; CTL 019; LG-740; tisagenlecleucel

Latest Information Update: 29 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lentigen Corporation; University of Pennsylvania
  • Developer Beijing Sanwater Biological Technology; Novartis; University of Pennsylvania
  • Class CAR-T cell therapies; Cell therapies; Gene therapies
  • Mechanism of Action CD19 antigen modulators; Gene transference; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Acute lymphoblastic leukaemia
  • Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Phase I B cell lymphoma; B cell prolymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma
  • Preclinical Breast cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 25 Jul 2017 Interim adverse events and efficacy data from the phase II JULIET trial in Diffuse large B cell lymphoma reported at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 12 Jul 2017 The US FDA's Oncologic Drugs Advisory Committee (ODAC) recommends approval of tisagenlecleucel-T for Acute lymphoblastic leukaemia (In children, In adolescents, Second-line therapy or greater) in USA
  • 06 Jul 2017 Oxford BioMedica enters into a supply agreement (extension of existing agreement) with Novartis for the LentiVector® technology, tisagenlecleucel-T and other CAR T cell therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top